Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients with Type 2 Diabetes

Moura, Filipe; Berg, David; Bellavia, Andrea; Dwyer, Jamie P; Mosenzon, Ofri; Scirica, Benjamin M; Wiviott, Stephen D; Bhatt, Deepak L; Raz, Itamar; Feinberg, Mark W.; Braunwald, Eugene; Morrow, David A; S. Sabatine, Marc

doi:10.25376/hra.23932914.v1

- No file added yet -

Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients with Type 2 Diabetes

journal contribution

posted on 2023-08-11, 16:37 authored by Filipe Moura, David Berg, Andrea Bellavia, Jamie P Dwyer, Ofri Mosenzon, Benjamin M Scirica, Stephen D Wiviott, Deepak L Bhatt, Itamar Raz, Mark W. Feinberg, Eugene Braunwald, David A Morrow, Marc S. Sabatine

A novel risk model for kidney disease progression was developed and applied to stratify risk in pts with T2DM.

History

Grant ID

20SFRN35120087

Usage metrics

Keywords

Risk Assessment Kidney Disease SGLT2i Diabetes

Licence

CC BY 4.0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients with Type 2 Diabetes

History

Grant ID

Usage metrics

Categories

Keywords

Licence

Exports